191 related articles for article (PubMed ID: 23729783)
1. Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer.
Chen JQ; Bao Y; Lee J; Murray JL; Litton JK; Xiao L; Zhou R; Wu Y; Shen XY; Zhang H; Sahin AA; Katz RL; Bondy ML; Berinstein NL; Hortobagyi GN; Radvanyi LG
Ann Oncol; 2013 Oct; 24(10):2534-2542. PubMed ID: 23729783
[TBL] [Abstract][Full Text] [Related]
2. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer.
Chen JQ; Litton J; Xiao L; Zhang HZ; Warneke CL; Wu Y; Shen X; Wu S; Sahin A; Katz R; Bondy M; Hortobagyi G; Berinstein NL; Murray JL; Radvanyi L
Horm Cancer; 2010 Feb; 1(1):21-33. PubMed ID: 21761348
[TBL] [Abstract][Full Text] [Related]
3. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer.
Chen JQ; Bao Y; Litton J; Xiao L; Zhang HZ; Warneke CL; Wu Y; Shen X; Wu S; Katz RL; Sahin A; Bondy M; Murray JL; Radvanyi L
Horm Cancer; 2011 Apr; 2(2):132-43. PubMed ID: 21761336
[TBL] [Abstract][Full Text] [Related]
4. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
5. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
6. [Roles of trichorhinophalangeal syndrome-1 gene in normal breast development and breast cancer].
Bao Y; Zhong ZX; Cui G; Guo L; Wang ZF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):121-4. PubMed ID: 23469802
[TBL] [Abstract][Full Text] [Related]
7. Utility of TRPS-1 immunohistochemistry in diagnosis of metastatic breast carcinoma in cytology specimens.
Abdelwahed M; Yurtsever N; Savant D; Karam P; Gimenez C; Das K; Sheikh-Fayyaz S; Khutti S
J Am Soc Cytopathol; 2022; 11(6):345-351. PubMed ID: 36055933
[TBL] [Abstract][Full Text] [Related]
8. Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer.
Su P; Hu J; Zhang H; Jia M; Li W; Jing X; Zhou G
Diagn Pathol; 2014 Jun; 9():119. PubMed ID: 24934762
[TBL] [Abstract][Full Text] [Related]
9. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
10. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
11. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
[TBL] [Abstract][Full Text] [Related]
12. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma.
El-Gendi SM; Mostafa MF
Pathol Oncol Res; 2016 Jul; 22(3):461-70. PubMed ID: 26597806
[TBL] [Abstract][Full Text] [Related]
13. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
van Nes JG; de Kruijf EM; Putter H; Faratian D; Munro A; Campbell F; Smit VT; Liefers GJ; Kuppen PJ; van de Velde CJ; Bartlett JM
Breast Cancer Res Treat; 2012 May; 133(1):49-59. PubMed ID: 21796367
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
16. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
18. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
20. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]